Literature DB >> 9537234

Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers.

S Nomoto1, N Haruki, M Kondo, H Konishi, T Takahashi, T Takahashi, T Takahashi.   

Abstract

We examined 61 lung cancer cases to determine whether alterations of p73, a novel monoallelically expressed p53-like molecule, may be involved in the pathogenesis of lung cancer. Allelic loss at the p73 locus at 1p36.33 was observed in 42% (11 of 26 informative cases), and squamous cell carcinoma tended to carry this lesion most frequently. Somatic mutations in the p73 gene itself, however, were not detected, despite our extensive search. We found interindividual difference in the allelic expression of p73 in normal lung, as well as intertissue variance, even within the same individual, but preferential loss of the expressed allele appeared to be an unlikely mechanism for p73 inactivation. This study, consequently, suggests the presence of an as yet unidentified tumor suppressor gene or genes within the subtelomeric region of 1p, warranting further studies aimed at its isolation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537234

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  The human p73 promoter: characterization and identification of functional E2F binding sites.

Authors:  Ratnam S Seelan; Meredith Irwin; Petra van der Stoop; Chiping Qian; William G Kaelin; Wanguo Liu
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Mutation and expression of the p51 gene in human lung cancer.

Authors:  M Tani; K Shimizu; C Kawahara; T Kohno; O Ishimoto; S Ikawa; J Yokota
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

3.  Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines.

Authors:  X T Kong; V A Valentine; S T Rowe; M B Valentine; S T Ragsdale; B G Jones; D A Wilkinson; G M Brodeur; S L Cohn; A T Look
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

4.  DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1.

Authors:  Mirko Marabese; Faina Vikhanskaya; Cristina Rainelli; Toshiyuki Sakai; Massimo Broggini
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

5.  DeltaNp73beta is active in transactivation and growth suppression.

Authors:  Gang Liu; Susan Nozell; Hui Xiao; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

6.  Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients.

Authors:  Amira Toumi Arfaoui; Lilia Ben Mahmoud Kriaa; Olfa El Amine El Hadj; Majid A Ben Hmida; Myriam Khiari; T Khalfallah; Lasaad Gharbi; Sabeh Mzabi; Sadaa Bouraoui
Journal:  Virchows Arch       Date:  2010-07-20       Impact factor: 4.064

7.  E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53.

Authors:  S Wienzek; J Roth; M Dobbelstein
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  ERBB receptor feedback inhibitor 1 regulation of estrogen receptor activity is critical for uterine implantation in mice.

Authors:  Tae Hoon Kim; Dong-Kee Lee; Heather L Franco; John P Lydon; Jae-Wook Jeong
Journal:  Biol Reprod       Date:  2009-12-16       Impact factor: 4.285

Review 9.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

10.  Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population.

Authors:  Benyuan Deng; Fei Liu; Yonggang Wei; Limei Luo; Xi Chen; Lvnan Yan; Bo Li
Journal:  Tumour Biol       Date:  2012-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.